Daniel Yadegar

Director/Miembro de la Junta en LUMOS PHARMA, INC. .

Consumer Services

Finance

Health Technology

Perfil

Daniel Yadegar is the founder of Newpath Management LP, founded in 2018.
Dr. Yadegar currently holds the positions of Director at Lumos Pharma, Inc. and Managing Partner at Double Point Ventures LLC.
Dr. Yadegar completed undergraduate education at Harvard University in 1999 and graduate education at Weill Cornell Medical College in 2004.

Cargos activos de Daniel Yadegar

Empresas	Cargo	Inicio
LUMOS PHARMA, INC.	Director/Miembro de la Junta	-
Newpath Management LP Newpath Management LP Investment ManagersFinance Newpath Partners invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and life sciences sectors. It provides financing for early stage capital requirements.	Fundador	01/09/2018

Todos los cargos activos de Daniel Yadegar

Formación de Daniel Yadegar.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Daniel Yadegar.

Relaciones

100 +

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	4
Harvard University Harvard University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Weill Cornell Medical College Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Newpath Management LP Newpath Management LP Investment ManagersFinance Newpath Partners invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and life sciences sectors. It provides financing for early stage capital requirements.	Finance
Lumos Pharma, Inc. Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases	Health Technology